ReviewCurrent drug research reviews2025
An Overview of Colon Specific Drug Delivery: Approaches and Evaluation Aspects.
Review in Current drug research reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- From Nature to Pharmacy: A Review of Tectoridin for Modern Therapeutics.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Molecular Targeting of EGFR, BRAF, and HER2 Signaling in Colorectal Cancer: Contemporary Advances with Panitumumab, Encorafenib, and Tucatinib.Journal of clinical medicine · 2026Review
- Exploring Recent Advances in Colon-targeted Drug Delivery Systems: from Traditional Methods to Advanced Technologies.Current gastroenterology reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Colon-specific Drug Delivery Systems (CDDS) are advantageous, especially in the targeted therapy of colonic disorders such as Inflammatory Bowel Diseases (IBD), amoebiasis, and Colorectal Cancer (CRC). Site-specific drug release enables achieving a high drug level at the targeted site and reduces adverse effects. The drug targeting can be achieved with zero or minimal drug releases into the non-targeted area, especially at the stomach and small intestine sites, with maximum releases into the site of action.
objectivesThis article focused primarily on reviewing the literature on product development of CDDS using approaches viz., pH-dependent, time-dependent, microbial-triggered, and combination approaches of two or more strategies for achieving possible drug releases and targeting successfully.
methodsThis review highlights the contributions of researchers in recent years to the field of CDDS, including various effective formulation designs and optimization, targeting approaches, factors affecting colon targeting, and evaluation parameters.
conclusionThis review article broadly covers recent advancements in the optimization and designing of novel CDDS with newer technologies in managing colon-specific diseases. It is concluded that CDDS is advantageous for the successful targeting of drugs to the colon region for effective management of colonic diseases.
Indexed as
Identifiers
41239792What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.